News stories about Iradimed (NASDAQ:IRMD) have trended somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Iradimed earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.0025769901722 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several equities analysts have recently weighed in on the stock. Roth Capital assumed coverage on shares of Iradimed in a research report on Tuesday, October 31st. They issued a “buy” rating and a $16.00 price objective on the stock. Credit Suisse Group assumed coverage on shares of Iradimed in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 price objective on the stock. ValuEngine raised shares of Iradimed from a “sell” rating to a “hold” rating in a research report on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.33.

Iradimed (IRMD) opened at $13.10 on Friday. The firm has a market cap of $138.27, a PE ratio of 100.77 and a beta of 1.61. Iradimed has a 1 year low of $7.85 and a 1 year high of $15.00.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.35. The company had revenue of $5.69 million for the quarter, compared to analyst estimates of $5.60 million. Iradimed had a net margin of 3.38% and a return on equity of 2.43%. The company’s revenue was down 25.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 earnings per share. equities analysts anticipate that Iradimed will post 0.05 EPS for the current fiscal year.

In related news, Director Monty K. Allen sold 1,898 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $13.95, for a total transaction of $26,477.10. Following the transaction, the director now directly owns 9,062 shares of the company’s stock, valued at $126,414.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 60.10% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at

Iradimed Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with Analyst Ratings Network's FREE daily email newsletter.